Texas Share of Cost, Axanum And Expanded Nexium Indication Rejected By FDA

Monday, Nov. 29th 2010 6:47 AM

Texas Share of Cost, Axanum And Expanded Nexium Indication Rejected By FDA: The Food and Drug Administration (FDA), USA has denied approval of AstraZeneca’s Axanum (aspirin plus esomeprazole magnesium) and an expanded indication for AstraZeneca’s Nexium (esomeprazole magnesium). AstraZeneca received a CRL (Complete Response Letter) for the new drug application for Axanum tablets, as well as a CRL for the supplemental new drug application (sNDA) for Nexium…

VN:F [1.9.22_1171]
Rating: 5.0/5 (1 vote cast)
VN:F [1.9.22_1171]
Rating: +1 (from 1 vote)
Texas Share of Cost, Axanum And Expanded Nexium Indication Rejected By FDA, 5.0 out of 5 based on 1 rating
Posted on Monday, Nov. 29th 2010 6:47 AM | by Share of Cost | in Share of Cost | No Comments »

Leave a Reply